| |
| Issue |
Title |
| |
| Vol 62, No 5 (2024) |
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results |
Abstract
PDF (Rus)
|
|
T. V. Beketova, N. O. Levina, Yu. A. Uskova, I. V. Rozanova, M. V. Dubinskaia, S. A. Evdokimova, V. V. Babak, M. F. Beketova, A. V. Devyatkin |
| |
| Vol 62, No 1 (2024) |
Risk factors for severe COVID-19 in patients with rheumatic diseases |
Abstract
PDF (Rus)
|
|
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| |
| Vol 61, No 5 (2023) |
Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology) |
Abstract
PDF (Rus)
|
|
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| |
| Vol 61, No 4 (2023) |
Rheumatoid arthritis and COVID-19: Three years later |
Abstract
PDF (Rus)
|
|
B. S. Belov, E. S. Aronova, G. I. Gridneva, E. I. Nasonov |
| |
| Vol 61, No 3 (2023) |
The use of the combined vector vaccine GamCOVID-Vac (Sputnik V) in patients with immuno-inflammatory rheumatic diseases: safety issues-news |
Abstract
PDF (Rus)
|
|
A. N. Kulikov, N. V. Muravyeva, B. S. Belov, S. I. Glukhova |
| |
| Vol 61, No 2 (2023) |
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab |
Abstract
PDF (Rus)
|
|
T. V. Beketova, N. О. Levina, M. V. Dubinskaia, Yu. A. Uskova, I. V. Rozanova, V. V. Babak, M. F. Beketova, T. N. Krasnova |
| |
| Vol 61, No 1 (2023) |
Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic |
Abstract
PDF (Rus)
|
|
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev |
| |
| Vol 61, No 1 (2023) |
Multifocal osteonecrosis as a consequence of a new coronavirus infection |
Abstract
PDF (Rus)
|
|
A. A. Klimenko, N. A. Demidova, D. Yu. Andryashkina, N. M. Babadayeva, A. A. Kondrashov, Yu. M. Saakyan |
| |
| Vol 61, No 1 (2023) |
COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics |
Abstract
PDF (Rus)
|
|
E. F. Iskhakova, E. V. Sukhorukova, M. Yu. Badeeva, E. V. Dyakova, S. A. Lapshina, T. V. Beketova, D. I. Abdulganieva |
| |
| Vol 60, No 6 (2022) |
Avascular necrosis of the epiphyses of bones in patients who have had SARS-CoV-2 infection: Clinical observations and a narrative review of literature data |
Abstract
PDF (Rus)
|
|
V. E. Bialik, A. E. Karateev, E. I. Bialik, M. A. Makarov, S. A. Makarov, A. A. Roskidailo, V. A. Nesterenko, A. M. Lila, M. A. Malygina |
| |
| Vol 60, No 4 (2022) |
Avascular necrosis as a part of post-COVID syndrome. Case reports |
Abstract
PDF (Rus)
|
|
T. V. Beketova, N. O. Levina, D. O. Ladygina, V. V. Babak, M. F. Beketova, T. N. Krasnova |
| |
| Vol 60, No 4 (2022) |
COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth |
Abstract
PDF (Rus)
|
|
O. A. Krichevskaya, T. V. Dubinina, E. V. Ilinykh, A. B. Demina, I. A. Andrianova |
| |
| Vol 60, No 3 (2022) |
Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis |
Abstract
PDF (Rus)
|
|
Sh. F. Erdes |
| |
| Vol 60, No 3 (2022) |
Autoantibodies and SARS-CoV-2 infection: A case report |
Abstract
PDF (Rus)
|
|
T. I. Kalenchic, S. L. Kabak, I. V. Korenevskaya |
| |
| Vol 60, No 3 (2022) |
Rheumatoid arthritis and post-COVID-19 syndrome |
Abstract
PDF (Rus)
|
|
Ch. T. Baimukhamedov, A. K. Botabekova, G. N. Dossybayeva, Sh. A. Makhmudov |
| |
| Vol 60, No 2 (2022) |
Effect of COVID-19 coronavirus infection on the course of rheumatoid arthritis |
Abstract
PDF (Rus)
|
|
V. N. Sorotskaya, A. O. Plakhova, B. B. Halmuradova, D. S. Vaisman, R. M. Balabanova |
| |
| Vol 60, No 2 (2022) |
On the issue of post COVID-19 condition in patients with rheumatic diseases |
Abstract
PDF (Rus)
PDF (Eng)
|
|
M. F. Beketova, V. V. Babak, M. D. Suprun, T. V. Beketova, O. A. Georginova |
| |
| Vol 60, No 2 (2022) |
The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
Abstract
PDF (Rus)
|
|
A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, E. S. Filatova, V. N. Amirjanova, S. I. Glukhova, E. G. Zotkin, A. M. Lila |
| |
| Vol 60, No 1 (2022) |
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues |
Abstract
PDF (Rus)
|
|
B. S. Belov, A. M. Lila, E. L. Nasonov |
| |
| Vol 59, No 6 (2021) |
Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic |
Abstract
PDF (Rus)
|
|
A. B. Borisova, T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov |
| |
| Vol 59, No 6 (2021) |
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, B. S. Belov, A. M. Lila, E. S. Aronova, G. I. Gridneva, A. V. Kudryavtseva, E. V. Sokol, A. V. Torgashina, I. B. Vinogradova, D. I. Abdulganieva, A. Yu. Zimenko |
| |
| Vol 59, No 4 (2021) |
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva |
| |
| Vol 59, No 3 (2021) |
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. M. Lila, V. I. Mazurov, B. S. Belov, A. E. Karateev, T. V. Dubinina, O. A. Nikitinskaya, A. A. Baranov, D. I. Abdulganieva, S. V. Moiseev, A. I. Zagrebneva |
| |
| Vol 59, No 3 (2021) |
“Post-COVID syndrome”: The focus is on musculoskeletal pain |
Abstract
PDF (Rus)
|
|
A. E. Karateev, V. N. Amirdzhanova, E. L. Nasonov, A. M. Lila, L. I. Alekseeva, E. Yu. Pogozheva, E. S. Filatova, V. A. Nesterenko |
| |
| Vol 59, No 3 (2021) |
Problems in patient management and the impact of osteoporosis therapy on the incidence of clinical infection |
Abstract
PDF (Rus)
|
|
O. M. Lesnyak, E. N. Gladkova, K. E. Zotkina, A. L. Grigoryeva, Yu. A. Safonova, O. Yu. Kuznetsova, M. A. Pokhaznikova |
| |
| Vol 59, No 1 (2021) |
COVID-19 and rheumatology: A year later |
Abstract
PDF (Rus)
|
|
B. S. Belov, A. M. Lila |
| |
| Vol 59, No 1 (2021) |
The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic |
Abstract
PDF (Rus)
PDF (Eng)
|
|
T. V. Beketova, V. V. Babak, M. D. Suprun |
| |
| Vol 59, No 1 (2021) |
Coronavirus disease 2019 (COVID-19) and autoimmunity |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| 1 - 28 of 28 Items |
|
